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Abstract
Background: Changes in microRNA (miRNA) expression patterns have been extensively characterized in several
cancers, including human colon cancer. However, how these miRNAs and their putative mRNA targets contribute
to the etiology of cancer is poorly understood. In this work, a bioinformatics computational approach with miRNA
and mRNA expression data was used to identify the putative targets of miRNAs and to construct association
networks between miRNAs and mRNAs to gain some insights into the underlined molecular mechanisms of
human colon cancer.
Method: The miRNA and mRNA microarray expression profiles from the same tissues including 7 human colon
tumor tissues and 4 normal tissues, collected by the Broad Institute, were used to identify significant associations
between miRNA and mRNA. We applied the partial least square (PLS) regression method and bootstrap based
statistical tests to the joint expression profiles of differentially expressed miRNAs and mRNAs. From this analysis, we
predicted putative miRNA targets and association networks between miRNAs and mRNAs. Pathway analysis was
employed to identify biological processes related to these miRNAs and their associated predicted mRNA targets.
Results: Most significantly associated up-regulated mRNAs with a down-regulated miRNA identified by the
proposed methodology were considered to be the miRNA targets. On average, approximately 16.5% and 11.0% of
targets predicted by this approach were also predicted as targets by the common prediction algorithms
TargetScan and miRanda, respectively. We demonstrated that our method detects more targets than a simple
correlation based association. Integrative mRNA:miRNA predictive networks from our analysis were constructed
with the aid of Cytoscape software. Pathway analysis validated the miRNAs through their predicted targets that
may be involved in cancer-associated biological networks.
Conclusion: We have identified an alternative bioinformatics approach for predicting miRNA targets in human
colon cancer and for reverse engineering the miRNA:mRNA network using inversely related mRNA and miRNA joint
expression profiles. We demonstrated the superiority of our predictive method compared to the correlation based
target prediction algorithm through a simulation study. We anticipate that the unique miRNA targets predicted by
the proposed method will advance the understanding of the molecular mechanism of colon cancer and will
suggest novel therapeutic targets after further experimental validations.
Background
Colon cancer is the third most common cancer in the
United States [1] and contributes to over 655,000 deaths
per year worldwide. However when diagnosed early, it is
one of the most treatable cancers [2]. Many efforts are
focused on detection rates and screening utilization
[3,4]. The primary treatment for colon cancer may
involve surgery, chemotherapy, biological therapy or
radiation [5]. Unfortunately, these treatments often
damage normal cells and tissues, so side effects are
common as are the possibilities of drug resistance and
disease recurrence [6]. Therefore, the identification of
new biomarkers for early diagnosis and prognosis of
human colon cancer is of great interest. Furthermore,
such biomarkers might be useful for the development of
novel therapeutics.
Recently miRNAs have been suggested to be among
these potential biomarkers [7]. The miRNAs are short
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by causing transcript degradation or translational repres-
sion [8,9]. In animals, they have been found to regulate
a wide range of biological processes such as stem cell
maintenance, development, metabolism, host-viral inter-
action, differentiation, proliferation and apoptosis [10].
Their activities are also implicated in cancer progression
or suppression by affecting oncogenesis, growth, inva-
sion and metastasis [11]. Studies suggest that three of
these miRNAs, miR-15a, miR-16 [12,13] and let-7
[14,15] can function as tumor suppressors, while miR-
155 and miR-21 play roles in oncogenesis [16,17]. Many
studies have also shown that miRNAs play a critical role
in cancer initiation and progression. For example,
miRNA-135a and miR-135b are reported to be involved
in the initiation of human colon cancer by targeting the
adenomatous polyposis coli gene (APC) [18]. Alterations
in miRNA expression patterns are commonly associated
with numerous human cancers, such as colorectal can-
cer and chronic lymphocytic leukemia [19]. Lu et al.
used 218 miRNAs expression profiles from 334 samples,
including multiple human cancers, to obtain information
on the developmental lineage and differentiation state of
the tumors [20]. They found most miRNAs in tumors
were down-regulated compared to expression levels in
normal tissues. Thus, miRNA expression profiles may
be a useful tool in human cancer diagnosis and in
designing treatments strategies. Nevertheless, specific
targets of the abnormally expressed miRNAs and their
biological functions remain largely unknown. So, accu-
rately identifying those genes regulated by such miRNAs
and their biological functions in affecting cancer devel-
opment and progression is of utmost importance.
Although, an increasing number of miRNA targets
have been validated experimentally http://diana.cslab.
ece.ntua.gr/tarbase, a majority of miRNA targets are
currently unknown and bioinformatics algorithms
remain the primary means of predicting these putative
targets. The principles of these algorithms are based on
sequence complementarity, species conservation, ther-
modynamic stability, and site accessibility. Currently,
there are eight widely used algorithms for miRNA target
prediction (DIANA-microT 3.0, EIMMo, miRanda, miR-
Base, PicTar, PITA, RNA22 and TargetScan 5.1) [11].
However, the utility of these computational techniques
is limited by various factors including miRNA size, iden-
tification of 3´ UTR and conservation analysis [19].
Furthermore, to our knowledge, none of these algo-
rithms incorporate high-throughput microarray gene
expression profiling data to predict miRNA targets.
As many miRNAs initiate the degradation of target
mRNA transcripts [8], simultaneous expression profiles
of miRNAs and mRNAs should reveal the existence of
such inverse relationships. Huang et al. in 2007 was the
first to utilize paired expression profiles of miRNAs and
mRNAs to identify functional miRNA targets using a
Bayesian data analysis algorithm (GeneMiR++) [21].
More recently, a similar strategy was used to identify
hepatitis C virus (HCV)-associated miRNA-mRNA regu-
latory modules [22]. However, the integrative computa-
tional method used in that paper was based on the
similarities in the expression profiles of miRNAs and
mRNAs across samples to calculate a simple miRNA-
mRNA correlation matrix. This pairwise correlation
method may grossly undermine the existing collineari-
ties amongst the covariates. The complex interrelation-
ship of multiple miRNAs influencing the expression of
one mRNA can be modeled by a regression method.
H o w e v e r ,d u et ot h el a r g en u m b e ro fm i R N A sc o m -
pared to the sample size and the existing collinearities
amongst the covariates (miRNAs) it is impossible to use
an ordinary linear regression model. So we use PLS
regression model to cope with these issues. Associations
between gene expression profiles have been previously
studied using a PLS regression approach in [23]. Since
then several others have proposed using PLS in the
microarray and proteomics contexts [24-27]. Standard
linear regression is not applicable for microarray gene
expression data where the number of covariates far
exceeds the sample size. PLS is a method for construct-
ing predictive models when there are numerous covari-
ates and many of them are highly collinear. To the best
of our knowledge, a PLS regression method has not
been used previously to integrate miRNA and mRNA
microarray data to predict miRNA targets.
Thus, the PLS regression method was used to explore
the likely associations/interactions between miRNA and
mRNA using expression data previously collected from
7 colon tumors [20]. We have used Pathway analysis to
understand the biological processes linked to these miR-
NAs and their predicted target mRNAs in the context
of colorectal cancer.
Results
Outline of our analysis
We used a multi-step approach in our analysis. In STEP
1, an un-paired t-test was used with FDR correction
methods to identify differentially expressed miRNAs and
mRNAs in colon tumors and normal colon tissues. In
STEP 2, the PLS regression method and statistical tests
on the association measures were performed. Repeated
bootstrap samples were used to identify significant asso-
ciations/interactions between miRNA and mRNA using
31 down-regulated miRNAs and 71 up-regulated
mRNAs. This PLS-bootstrap algorithm work-flow is out-
lined in the Figure 1. In STEP 3, we compared the pre-
dictions from our PLS regression method with those
from TargetScan 5.1 and miRanda. In STEP 4, a gene
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way Studio software. In STEP 5, miRNA-mRNA inter-
acting networks were developed with the aid of
Cytoscape 2.7 software. In STEP 6 and 7, IPA and IPA
pathway designer were used to create a functional analy-
sis of biological processes related to miRNAs and their
target mRNAs. Finally, in STEP 8, a simulation was per-
formed to evaluate the false detection rate for PLS.
Steps 1-3 can be considered as the discoveries after
mining the real data and Steps 6-8 correspond to the
validities of these mined results.
STEP 1. Differentially expressed miRNA and mRNA in
human colon tissues
The miRNA and mRNA microarray expression profiles
from the same tissues including 7 human colon tumor
tissues and 4 normal tissues were analyzed with the aid
of GeneSpring GX10 software (Agilent, CA). The Benja-
mini & Hochberg FDR (false discovery rate) was used to
obtain adjusted p-values for unpaired t-tests [28]. Differ-
entially expressed miRNAs and mRNAs with adjusted p-
values less than or equal to 10% and the absolute fold
changes greater than or equal to 1.2 were obtained. We
found a total of 31 down-regulated miRNAs and 2 up-
regulated miRNAs that fit these criteria (Additional file
1, table S1). In addition, we found 73 up-regulated
mRNAs and 63 down-regulated mRNAs (Additional file
2, table S2). Some of the mRNAs did not have gene IDs.
There were only two up-regulated miRNAs using the
above mentioned cutoff. Therefore, in this study we
selected the 31 down-regulated miRNAs and the 71 up-
regulated mRNAs to find the most likely miRNA:mRNA
negative/inverse associations with the aid of the PLS
regression method. Among the differentially expressed
miRNAs, only miR-135b and miR-221 are significantly
up-regulated (4.3 and 1.7 fold, respectively) in the colon
cancer tissue samples. The remaining 31 miRNAs
(Additional file 1, table S1) were significantly down-
regulated in these samples.
STEP 2. miRNA:mRNA Associations predicted by PLS
To identify the most likely prospective targets the 31
down-regulated miRNAs were used as independent vari-
ables and the 71 mRNAs were denoted as dependent
variables in the PLS regression analysis. Subsequently,
statistical tests were performed to identify significant
negative associations between each mRNA with the 31
down-regulated miRNAs. The algorithm flow diagram
for this multi-step procedure is shown in Figure 1.
Table 1 lists the 31 down-regulated miRNAs and their
associated target mRNAs predicted by the PLS regres-
sion method. The maximum number of predicted
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5. Ran PLS with new Y 
variables and 31 miRNAs
and calculated the new 
associated scores and 
repeated bootstrarpping
for 1000 times
6. Calculated the proportion of times a specific 
association score is less than the observed 
association scores amongst all the 1000 
bootstrapped association scores, which were the 
estimated p-value. A small p-value implied strong 
miRNA-mRNA association/interaction
7. A Benjamini & Hochberg FDR correction to obtain 
an adjusted p-value. The mRNA which had strong 
association with a miRNA is deemed to be the target 
of that miRNA
1. Ran PLS with 71 
mRNA & 31 miRNA, 
calculated the 
association scores and  
stored them in a 71x31 
matrix
Figure 1 Algorithm to find miRNA targets. Illustrated is a workflow involving PLS and statistical testing to find the significant mRNA targets
for each down-regulated miRNA.
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Page 3 of 15Table 1 Identification of 31 down-regulated miRNAs from a list of 71 up-regulated mRNAs
Down-regulated
miRNA
miRNA
family
No. of mRNA
targets
Target genes predicted by the PLS method
*hsa-let-7 g Let-7 g 17 BUD31, COTL1, CPNE1, EIF3B, FTL, GTF3C1, IFITM1, NAP1L4, NUDT1, PHB, PSMC2, PSMC4, PUF60, Ras-
Like protein, RPL10, SRD5A3, WDR36
hsa-miR-1 miR-1 1 RPL10
hsa-miR-100 miR-100 1 GSTP1
*hsa-miR-101 miR-101 7 ATP6V0B, GTF2IRD1, GUK1, NEBL, PSMB4, UBE2I, VKORC1
hsa-miR-10b miR-10b 2 MIF, PSMC2
hsa-miR-126 miR-126 16 ANXA2, CSTB, DDIT4, GPATCH3, GTF2IRD1, GUK1, MDK, NDK, NEBL, OAZ1, PSMB4, S100A11, SLC7A11,
TBCD, UBA6, VKORC1
hsa-miR-130a miR-130 2 GSTP1, RPL34
*hsa-miR-133a miR-133 17 ANXA2, ATP6V0B, CSTB, GPATCH3, GPX1, GTF2IRD1, NAP1L4, NEBL, OAZ1, POLR2H, PSMB4, RPL10,
SLC7A11, TBCD, UBA6, UBE2I, VKORC1
hsa-miR-142-5p miR-142 6 ARPC1B, DDIT4, GSTP1, MDK, TUFM, USP22
*hsa-miR-150 miR-150 20 ABHD12, C7orf28A, CLIC1, CPNE1, EIF3B, GSTP1, GTF3C1, IFITM1, LAPTM5, NAP1L4, ODC1, PRDX2,
PSMB2, PSMC4, PSMD8, PUF60, RPL10, SRD5A3, TBCD, Wilm’s tumor-related protein
*hsa-miR-15a miR-15 8 C7orf28A, CAPG, CPNE1, GTF3C1, NUDT1, PSMD8, WDR36, Wilm’s tumor-related protein
*hsa-miR-16 miR-16 8 FTL, GTF3C1, LAPTM5, PHB, PSMD8, SRD5A3, WDR36, Wilm’s tumor-related protein
hsa-miR-195 miR-195 2 PSMD8, RPL10
hsa-miR-26a miR-26 3 CAPG, FTL, GTF3C1
hsa-miR-26b miR-26 15 ATP6V0B, BUD31, CANX, CAPG, EIF3B, FTL, MIF, NAP1L4, NUDT1, ODC1, POLR2H, PSMC2, PSMC4,
UBE2I, WDR36
hsa-miR-28 miR-28 21 ABHD12, ARPC1B, CLIC1, CPNE1, EIF3B, FTL, GTF3C1, IFITM1, LAPTM5, NAP1L4, ODC1, PRDX2, PSMB2,
PSMC4, PSMD8, PUF60, RPL10, RPS9, SRD5A3, TUFM, Wilm’s tumor-related protein
*hsa-miR-29b miR-29 15 ANXA2, CDC42SE1, CSTB, DDIT4, GNPTG, GPATCH3, GPX1, ITPA, MDK, PSMB4, S100A11, SLC7A11,
USP22, VKORC1, ZNF37A
*hsa-miR-29c miR-29 7 ABHD12, C7orf28A, PSMD8, RPL10, TBCD, USP22, ZNF37A
*hsa-miR-30a miR-30 22 ANXA2, C7orf28A, CAPG, CSTB, DAP, GPATCH3, GPX1, GTF2IRD1, GUK1, ITPA, MMP11, NEBL, NUDT1,
OAZ1, POLR2H, PSMB4, SLC7A11, TBCD, UBA6, UBE2I, VKORC1, ZNF37A
*hsa-miR-30b miR-30 20 ANXA2, CDC42SE1, CSTB, DDIT4, GNPTG, GPATCH3, GPX1, GPX4, GSTP1, GTF2IRD1, ITPA, MDK, NDK,
OAZ1, PSMB4, S100A11, SLC7A11, USP22, VKORC1, ZNF37A
*hsa-miR-30c miR-30 15 ANXA2, CSTB, GPATCH3, GSTP1, GTF2IRD1, ITPA, MDK, NDK, OAZ1, PSMB4, S100A11, SLC7A11, UBA6,
VKORC1, ZNF37A
*hsa-miR-30d miR-30 25 ANXA2, ATP6V0B, BHLHE40, C7orf28A, CAPG, CDC42SE1, CSTB, DAP, DDIT4, GPATCH3, GPX1,
GTF2IRD1, MIF, MMP11, NEBL, POLR2H, PSMB4, RPL10, S100A11, SLC7A11, TBCD, UBA6, UBE2I,
VKORC1, ZNF37A
*hsa-miR-30e miR-30 17 ATP6V0B, BHLHE40, C7orf28A, CAPG, CSTB, DAP, GPATCH3, GPX1, MMP11, NEBL, NUDT1, OAZ1,
POLR2H, RPL10, TBCD, VKORC1, ZNF37A
hsa-miR-32 miR-32 5 C7orf28A, ODC1, PSMD8, RPL10, TBCD
*hsa-miR-34b miR-34 12 BUD31, CANX, EIF3B, FTL, GTF3C1, IFITM1, PHB, PSMC4, PUF60, RPL34, SRD5A3, WDR36
hsa-miR-99a miR-99 19 ANXA2, CSTB, DDIT4, GPATCH3, GSTP1, GTF2IRD1, MDK, MIF, NDK, NEBL, OAZ1, POLR2H, S100A11,
SLC7A11, TBCD, UBA6, UBE2I, VKORC1, ZNF37A
mmu-miR-10b miR-10 2 Ras-Like protein, WDR36
mmu-miR-151 miR-151 13 ATP6V0B, BHLHE40, C7orf28A, CAPG, GTF2IRD1, MIF, MMP11, NUDT1, OAZ1, POLR2H, RPL10, TBCD,
VKORC1
*mmu-miR-342 miR-342 21 ABHD12, ARPC1B, CLIC1, CPNE1, EIF3B, FTL, GTF3C1, IFITM1, NAP1L4, ODC1, PSMB2, PSMC4, PSMD8,
PUF60, RPL10, RPL34, RPS9, SRD5A3, TGFBI, TUFM, Wilm’s tumor-related protein
rno-miR-140 miR-140 1 NDK
rno-miR-151 miR-151 16 ANXA2, CDC42SE1, CSTB, DDIT4, GNPTG, GPATCH3, GPX1, GTF2IRD1, ITPA, MDK, MMP11, PSMB4,
S100A11, SLC7A11, USP22, ZNF37A
*miRNAs are selected as cancer-mediators based on the literature.
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Page 4 of 15targets was 25 for miR-30d, and the minimum number
of predicted targets was one for miR-1, miR-100 and
rno-miR-140 (Table 1). The number of predicted targets
for each member of the miR-30 family (a-e) was 22, 20,
15, 25 and 17, respectively. Table 2 lists the mRNAs for
each of those miRNAs which have been previously
reported to have associations with some form of cancer.
Table 2 also contains some additional results related to
STEP 3.
STEP 3. Comparisons between PLS Regression, TargetScan
5.1 and miRanda
Comparing the PLS regression method with other com-
putational miRNA-target prediction algorithms such as
TargetScan 5.1 and miRanda we found some areas of
agreement. Thus, some of the miRNA-targets predicted
by PLS were also predicted by either TargetScan or
miRanda or both of them (Table 2). This table provides
the number of miRNA-targets for those miRNAs report-
edly linked to cancer [29-42]. It shows the percentage of
common targets predicted by our use of the PLS regres-
sion method, with TargetScan 5.1 and miRanda.
Using 15 down-regulated miRNAs (let-7 g, miR-101,
miR-133a, miR-150, miR-15a, miR-16, miR-29b, miR-
29c, miR-30a, miR-30b, miR-30c, miR-30d, miR-30e,
miR-34b and miR-342), known to be associated with
cancer, we found 16.5% and 11.0% of our PLS-predicted
miRNA-targets, on average, were also predicted as tar-
gets for the corresponding miRNAs by TargetScan5.1
and miRanda, respectively (Table 2). Moreover, we
found that five out of 25 of our PLS-predicted targets
(20%) for miR-30d were also predicted as targets for this
miRNA by both TargetScan5.1 and miRanda. These five
target genes predicted by our PLS regression approach,
TargetScan 5.1 and miRanda were BHLHE40, DDIT4,
NEBL, SLC7A11 and UBE2I. In this regard, it is inter-
esting to note that our method identified more common
targets with TargetScan than miRanda. From Tables 1
and 2 it is evident that our analysis provides many novel
targets that were not identified by these existing algo-
rithms which may prove to be significant biomarkers for
colon cancer. In order to further pursue the integrative
analysis an association network for these significantly
associated miRNAs and mRNAs was constructed (see
STEP 5).
STEP 4. Gene ontology (GO) terms for miRNA-targets in
the category of biological processes
To gain further insight into the biological functions of
each miRNA and its predicted targets, the 71 up-regu-
lated mRNAs from the colon cancer microarray were
first analyzed with the aid of Pathway Studio 7 (Ariadne
Genomics Inc., Rockville, MD, USA). This analysis was
used to obtain the gene ontological (GO) terms for the
category of biological processes. We selected three of
the most significant GO terms with all of the unadjusted
p-values less than 0.02 except one function termed DNA
replication which had a p-value 0.05. The corresponding
adjusted p-values were less than 0.06 and 0.13 respec-
tively. Almost all the terms are significant at FDR 10%.
The remaining term is significant at FDR 13%. In Table
3 the significant GO terms associated with the predicted
targets for 15 miRNAs linked to colorectal cancer tis-
sues are listed as biological processes. The significant
Table 2 Identification of miRNA targets from 15 down-regulated and 71 up-regulated mRNAs
Cancer-related and down-
regulated miRNA
miRNA
family
No. of target
mRNAs
No. (%) of overlapping PLS predicted
mRNAs with TargetScan5.1
No. (%) of overlapping PLS predicted
mRNAs with miRanda
hsa-let-7 g Let-7 g 16 0 2(12.5)
hsa-miR-101 miR-101 7 0 0
hsa-miR-133a miR-133 17 3(17.6) 2(11.8)
hsa-miR-150 miR-150 20 3(15.0) 1(5.0)
hsa-miR-15a miR-15 8 1(12.5) 1(12.5)
hsa-miR-16 miR-16 8 1(12.5) 0
hsa-miR-29b miR-29 15 3(20.0) 2(13.3)
hsa-miR-29c miR-29 7 2(28.6) 1(14.3)
hsa-miR-30a miR-30 22 3(13.6) 3(13.6)
hsa-miR-30b miR-30 20 4(20.0) 2(10.0)
hsa-miR-30c miR-30 15 1(6.7) 1(6.7)
hsa-miR-30d miR-30 25 7(28.0) 5(20.0)
hsa-miR-30e miR-30 17 3(17.6) 3(17.6)
hsa-miR-34b miR-34 12 3(25.0) 0
mmu-miR-342 miR-342 21 4(19.0) 1(4.8)
Total -- 16.5 11.0
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plex (APC)-dependent proteasomal ubiquitin-dependent
protein catabolic process, negative or positive regulation
of ubiquitin-protein ligase activity during mitotic cell
cycle, polyamine biosynthetic process, oxidative stress,
oxidation reduction, oxidoreductase activity, glutathione
peroxidase process, regulation of cell proliferation and
apoptosis, translational elongation and lipid metabolic
process. Interestingly, many of the target mRNAs
expressed in the colorectal cancer tissues and associated
with the miRNAs appear to be involved in protein
degradation and apoptosis and are linked to the oxida-
tive stress signal transduction pathway. Therefore, these
data highlight the oxidative stress mechanism that is
operative in colorectal cancer tissue.
STEP 5. Visualization of miRNA:mRNA association
networks
Using the statistically significant bij -association scores
between the i-th mRNA and j-th miRNA, derived from
the PLS regression method, we constructed association
networks including the significant miRNAs and
mRNAs. The resulting miRNA:mRNA association net-
work had 97 nodes and 155 connections between the
31 down-regulated miRNAs and the 71 up-regulated
mRNAs (Figure 2A). We developed a network to
demonstrate the overlapping miRNA targets for miR-
NAs in the miR-30 family (a-e) (Figure 2B) since these
miRNAs have a large number of mRNA targets. The
number of targets for miR-30 a-e was 22, 20, 15, 25 and
17, respectively (Table 3). This network (Figure 2B)
indicated that two mRNAs (VKORC1 and CSTB; in
red) were predicted to be targets of five miR-30 miR-
NAs, six mRNAs (ANXA2, GPATCH3, OAZ1, PSMB4,
SLC7A11, ZNF37A; in turquoise) were targeted by four
of the miRNAs, and ten mRNAs (CAPG, C7orf28A,
DAP, GPX1, ITPA, MMP11, NEBL, POLR2H, S100A11
and GTF2IRD1; 3 in green and 7 in blue) were targeted
by three of the miRNAs (Figure 2B). Networks were
also developed for the seven miRNAs (let-7 g, miR-101,
miR-133a, miR-15a, miR-16, miR-29b and miR-29c) clo-
sely related to cancer and their associated mRNAs (Fig-
ure 2C). Most of the targets mentioned here have been
reported to be linked to cancer. For example, ANXA2
up-regulation was reported to be associated with human
hepatocellular carcinoma, pancreatic adenocarcinoma,
high-grade glioma, gastric carcinoma, acute promyelocy-
t i cl e u k e m i aa n dp r i m a r yc olorectal cancer [43]. Also,
Table 3 Gene ontology (GO) terms for miRNA-targets in the category of biological processes
Cancer-related and down-
regulated miRNA
miRNA
family
No. of
mRNAs
GO terms
hsa-let-7 g Let-7 g 16 Anaphase-promoting complex(APC)-dependent proteasomal ubiquitin-dependent protein
catabolic process, response to oxidative stress and regulation of apoptosis
hsa-miR-101 miR-101 7 Ubiquitin-dependent protein catabolic process, APC-dependent proteasonmal ubiquitin-
dependent protein catabolic process and oxidoreductase activity
hsa-miR-133a miR-133 17 Polyamine biosynthetic process,glutathione peroxidase process, Ubiquitin-dependent protein
catabolic process and regulation of apoptosis
hsa-miR-150 miR-150 20 Polyamine biosynthetic process, APC-dependent proteasomal ubiquitin-dependent protein
catabolic process, Glutathione peroxidase activity
hsa-miR-15a miR-15 8 Anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic
process, response to oxidative stress and proteasome complex
hsa-miR-16 miR-16 8 APC-dependent proteasomal ubiquitin-dependent protein catabolic process, negative
regulation of cell proliferation and oxidoreductase activity
hsa-miR-29b miR-29 15 Regulation of cell proliferation, glutathione peroxidase activity and regulation of apoptosis
hsa-miR-29c miR-29 7 Ubiquitin-dependent protein catabolic process, APC-dependent proteasomal ubiquitin-
dependent protein catabolic process and translational elongation
hsa-miR-30a miR-30 22 Polyamine biosynthetic process, ubiquitin-dependent protein catabolic process, and regulation
of apoptosis
hsa-miR-30b miR-30 20 Ubiquitin-dependent protein catabolic process, polyamine biosynthetic process and oxidative
stress
hsa-miR-30c miR-30 15 Polyamine biosynthetic process, ubiquitin-dependent protein catabolic process, and regulation
of apoptosis
hsa-miR-30d miR-30 25 Regulation of apoptosis, glutathione peroxidase activity and ubiquitin-dependent protein
catabolic process
hsa-miR-30e miR-30 17 Polyamine biosynthetic process, response to oxidative stress and regulation of apoptosis
hsa-miR-34b miR-34 12 Regulation of cell proliferation, oxidoreductase activity and translational elongation
mmu-miR-342 miR-342 21 Polyamine biosynthetic process, translational elongation and APC-dependent proteasomal
ubiquitin-dependent protein catabolic process
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lated in colorectal cancer [44].
STEP 6. Pathway analysis with the aid of IPA
To gain additional insight into prospective miRNA
linked biological networks and canonical pathways, the
31 down-regulated miRNAs from the colon cancer
microarrays were analyzed with the aid of Ingenuity
Pathway Analysis (IPA) software. We focused on two
miRNA-associated networks related to cancer. The most
significant (top) functional pathways highlighted by IPA
consisted of 1) cancer, reproductive system disease, and
genetic disorders and 2) cell death, hematological system
development and function, and cancer. We found that
ten of the down-regulated miRNAs (miR101, miR26a,
miR26b, miR30a, miR30b, miR30d, miR30e, miR34b,
miR-let7 g and miRN140) were grouped together in a
functional network (Figure 3A) and nine of the down-
regulated miRNAs (miR-130a, miR-133a, miR-142, miR-
150, miR15a, miR-16, miR-29b, miR-30c and miR-99a)
were grouped together in a second network (Figure 3B).
These are colored in green in Figures 3A and 3B.
A.
B. C.
Figure 2 miRNA-mRNA association network. A. miRNA-mRNA interaction network with 97 nodes and 155 connections between 31 down-
regulated miRNAs and 71 up-regulated mRNAs. miRNAs are in yellow while mRNAs are in pink. B. A sub-network depicting miRNA-mRNA
interactions predicted from the miR-30 family. miRNAs are in yellow and mRNAs are in other colors. C. A sub-network depicting miRNA:mRNA
interactions predicted from other cancer-associated miRNAs: let-7 g, miR-101, miR-133a, miR-15a, miR-16, miR-29b and miR-29c.
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Page 7 of 15In parallel, we used IPA to investigate the 71 up-regu-
lated mRNAs. We were particularly interested in finding
biological networks, functions and canonical pathways
associated with these mRNAs that may be linked to
human cancers. Therefore, we focused on the four most
statistically significant networks with functions related
to tumor morphology, cell signaling, immunological dis-
ease, cellular growth and proliferation (Table 4), func-
tions of cancer (Table 5) and cancer-associated
canonical pathways (Table 6). The second column of
Table 4, 5 and 6 includes all genes associated with the
top four networks, function, or canonical pathways of
cancer which are also predicted by the PLS regression
method as possible miRNA targets.
STEP 7. Combinatorial analysis with the aid of the PLS
method and IPA pathway designer
For the above pathway analysis results from 31 down-
regulated miRNAs and 71 up-regulated mRNAs in the
previous step, we were interested in knowing which
miRNAs were associated with the mRNAs grouped in
the above cancer-related networks, functions and
A. B.
Figure 3 Top miRNA networks. A. miRNA-associated network with most statistically significant (top) functions related to cancer, reproductive
system disease, and genetic disorders. The ten miRNAs, colored green were presented in the list of 31 down-regulated miRNAs (Table 1). The
genes with white color are not from our data set and recruited by the IPA knowledge base. B. miRNA-associated network with top functions
related to cell death, hematological system development and function, and cancer. The nine miRNAs, colored green were also present in the list
of 31 down-regulated miRNAs.
Table 4 15 miRNAs and target genes involved in the cancer-related gene networks
Top
Network
Target genes Top functions The nos. of
miRNAs
associated
Network
1
BHLHE40, CANX, CDC42SE1, GPX1, GPX4, GSTP1, MDK, MIF, MMP11, OAZ1,
ODC1, PPIB, PRDX2, PSMA3, PSMB2, PSMB4, PSMC2, PSMC4, PSMD8, TGFBI,
UBE2I
small molecule biochemistry, drug
metabolism and tumor morphology
15
Network
2
ANXA2, CAPG, CLIC1, CPNE1, CSTB, DAP, EIF3B, GUK1, IFITM1, RPL34, RPS9,
SLC7A11, SOX4, TBCD, TUFM, USP22
protein synthesis, cell signaling and
interaction, and reproductive system
function,
14
Network
3
ATP6V0B, BHLHE40, COTL1, CYBA, DDIT4, FTL, ITPA, LAPTM5, NEBL, NUDT1,
RPS2, S100A11, SORD
genetic disorder, immunological disease
and free radical scavenging
14
Network
4
ANXA2, ARPC1B, BUD31, GNPTG, GPATCH3, GTF3C1, NAP1L4, PHB, POLR2H,
PUF60, UBA6, VKORC1, WDR36
gene expression, cellular development,
cellular growth and proliferation
14
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Page 8 of 15pathways predicted by our PLS regression method. With
the aid of IPA pathway designer we expanded the above
networks, functions and pathways generated by IPA
( F i g u r e3 ,T a b l e s4 ,5a n d6 )b yc o m b i n i n gt h eP L S
regression method and IPA pathway.
At first, we examined the two networks that were
mediated by miRNAs and that were generated from the
31 down-regulated miRNAs (Figure 3A and 3B). With
the aid of the IPA pathway designer, we connected
miRNA-targets predicted by the PLS regression method
with each associated miRNA labeled as my list (ML in
Figure 4A and 4B). These miRNAs in ML were con-
nected to the two networks (Figure 3A and 3B) through
their predicted targets by IPA. The new expanded net-
works from Figure 3A and 3B are shown in Figure 4A
and 4B. In Figure 4A, we found that 27 of 31 down-
regulated miRNAs were associated with the miRNA-
associated network through 15 genes (ANXA2,
A R P C 1 B ,B H L H E 4 0 ,G P X 1 ,M I F ,O A Z 1 ,O D C 1 ,P H B ,
PSMB4, RAN, RPL10, RPL34, RPS9, TUFM, UBE2I)
predicted by the PLS regression method. These mRNAs
are all included in the list of predicted target in Table 2.
It was interesting to see that the four remaining miR-
NAs (miR-100, rno-miR-140, miR15a and miR-26a)
were grouped in this network by IPA and not connected
through the above cancer-related target mRNAs by the
pathway designer and hence two of them (miR-100 and
miR-15a) were not included in Figure 4A. In this net-
work, many of the cancer-affected target mRNAs were
mainly regulated by the transcription factors MYCN and
FOXO1 which play a vital role in cell death, apoptosis,
proliferation and survival. Particularly MYCN was
involved in the ERK/MAPK signaling pathway and
cancer.
In a similar manner in Figure 4B, we found that 12 of
31-miRNAs were grouped with the miRNA-associated
network through their predicted targets (BHLHE40,
G P X 1 ,M D K ,S 1 0 0 A 9a n dU B E 2 I ) .T h e s ec a n c e r - a s s o -
ciated target mRNAs were connected to this network
mainly through the interaction with apoptosis and cell
Table 5 15 miRNAs and target genes involved in the cancer-related functions
Cancer. related
Function
PLS predicted Target genes in the respective functions The nos. of cancer related
miRNAs associated with the
mRNA targets
Cancer ANXA2, BHLHE40, CANX, CAPG, COTL1, CYBA, DDIT4, FTL, GPX1, GSTP1, IFITM1, MIF, MMP11,
OAZ1, ODC1, S100A11, SLC12A8, SLC7A11, SOX4 and UBE2I (20)
15
Tumorigenesis ANXA2, BHLHE40, CANX, CAPG, COTL1, CYBA, DDIT4, FTL, GPX1, GSTP1, IFITM1, MIF, MMP11,
NUDT1, OAZ1, ODC1, PRDX2, S100A11, SLC12A8, SLC7A11, SOX4 and UBE2I (22)
15
Carcinoma ANXA2, BHLHE40, CANX, COTL1, CYBA, FTL, GSTP1, IFITM1, MMP11, OAZ1, ODC1, S100A11
and SLC7A11 (13)
12
Malignant tumor ANXA2, BHLHE40, CANX, COTL1, CYBA, FTL, GPX1, GSTP1, IFITM1, MIF, MMP11, OAZ1, ODC1,
S100A11, SLC7A11 and SOX4 (16)
12
Primary tumor ANXA2, BHLHE40, CANX, COTL1, CYBA, FTL, GPX1, GSTP1, IFITM1, MIF, MMP11, OAZ1, ODC1,
PRDX2, S100A11, SLC7A11 and SOX4 (17)
12
Angiogenesis ANXA2, CANX and GPX1 (3) 8
Table 6 15 miRNAs and target genes in the cancer-related canonical pathways
Cancer related canonical pathway PLS predicted Target genes in the respective
pathways
The nos. of cancer related miRNAs associated with
the mRNA targets
Protein Ubiquitination Pathway PSMA3, PSMB2, PSMB4, PSMC2, PSMC4, PSMD8,
UBE2I, USP22(8)
14
Polyamine Regulation in Colon
Cancer
OAZ1, ODC1, PSMA3, PSMB2, PSMB4, PSMC2,
PSMC4, PSMD8(8)
15
Purine Metabolism ATP6V0B, GUK1, ITPA, POLR2H, PSMC2, PSMC4 (6) 11
Circadian Rhythm Signaling BHLHE40(1) 2
Hypoxia Signaling in the
Cardiovascular System
UBE2I(1) 4
Cdc42 Signaling ARPC1B, CDC42SE1(2) 4
Pyrimidine Metabolism ITPA, POLR2H (2) 7
mTOR Signaling DDIT4, EIF3B (2) 7
NRF2-mediated Oxidative Stress
Response
FTL, GSTP1, PPIB(3) 7
Xenobiotic Metabolism Signaling FTL, GSTP1(2) 7
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Page 9 of 15death genes such as BCL2, CASP9 and ELK1 (Figure
4B).
Next we examined the expanded IPA results from 71
up-regulated mRNAs which were shown in the last col-
u m no fT a b l e s4 ,5a n d6 .A tf i r s tw ew a n t e dt ok n o w
which of the 31 down-regulated miRNAs were asso-
ciated with the top four networks through their target
mRNAs predicted by PLS regression method. With the
aid of IPA pathway designer, we found that 27 of the 31
down-regulated miRNAs were linked to one or more
mRNA networks and 20 of them (let-7 g, miR-101,
miR-126, miR-133a, miR-142-5p, miR-150, miR-15a,
miR-26b, miR-28, miR-29b, miR-30a, miR-30b, miR-30c,
miR-30d, miR-30e, miR-34b, miR-99a, mmu-miR-151,
mmu-miR-342 and rno-miR-151) were involved in all of
the top 4 networks. By restricting our attention to only
the 15 cancer-associated miRNAs in the top four
mRNA networks, we found that all 15 miRNAs were
involved in network 1, all but miR-16 were in network
2 ,a n da l lb u tm i R - 2 9 cw e r ei nn e t w o r k3a n d4 ,a s
shown in the fourth column of Table 4.
We also checked which miRNAs associated with the
mRNA targets predicted by PLS regression method were
linked to the cancer-related function. Through their
targets, we found that 26 out of the 31 down-regulated
miRNAs were associated with these targets and were in
some ways related to cancer, 24 miRNAs were in the
pathway of polyamine regulation in colon cancer and 12
miRNAs were involved in angiogenesis pathway. Again,
we were interested in examining the 15 miRNAs directly
linked with cancer-and their biological functions. We
found that all 15 miRNAs were involved in cancer and
tumorigenesis, 12 of them (all except miR-101, miR-15a
and miR-29c) were in carcinoma, malignant tumor and
primary tumor and 8 of them (all except let-7 g, miR-
101, miR-150, miR-15a, miR-16, miR-29c and miR-342)
were in angiogenesis as were shown in the last column
of Table 5.
Furthermore, we examined which associated miRNAs
among the 15 cancer-related miRNAs were involved in
the canonical pathways associated with cancer. We
found that 14 miRNAs were associated with protein ubi-
quitination pathway, all 15 miRNAs were in polyamine
regulation in colon cancer, 11m i R N A sw e r ea s s o c i a t e d
with purine metabolism, 2 miRNAs were associated
with circadian rhythm signaling, 4 miRNAs each were
associated with hypoxia signaling in cardiovascular sys-
tem and cdc42 signaling, and 7 miRNAs each were
A. B.
Figure 4 Overlaid networks predicted by the PLS method and generated by IPA pathway designer. A. Depicted is an overlaid miRNA-
mediated network consisting of the top network 1 from Figure 3A on the left side of this network (green-colored miRNAs) and 27 miRNAs
labeled with ML on the right that were significantly associated with the pink-colored mRNAs that were predicted by PLS. B. Depicted is an
overlaid miRNA-mediated network consisting of the top network 2 from the Figure 3B on the left side of this network (green-colored miRNAs)
and 12 miRNAs labeled with ML on the right that were significantly associated with the pink-colored mRNAsthat were predicted by PLS.
Li et al. BMC Medical Genomics 2011, 4:44
http://www.biomedcentral.com/1755-8794/4/44
Page 10 of 15associated with pyrimidine metabolism, mTOR signaling
or NRF2-mediated oxidative stress response or xenobio-
tic metabolism signaling along and their targets are
mentioned in the last column of Table 6.
Overall, it clearly showed that these cancer-related
miRNAs may mediate many biological functions and
pathways by regulating the target genes predicted by our
integrative and computational method.
STEP 8. Estimating false detection rate for PLS based
target prediction
In order to determine the false detection rate of our
mRNA target prediction method using PLS regression we
used a simulation experiment. As defined in [22], the false
detection rate is the percentage of detected significant
miRNA-mRNA pairs derived as output from the PLS
method out of the total possible pairs that would have the
same or better associations by chance. Based on this pro-
cedure, the estimated false detection rate for the threshold
FDR of 0.3 was 2.50%. We then reported the estimated
false detection rates for many values of the thresholds
simultaneously, and the estimated false detection rate is
plotted as a function of the threshold in Figure 5.
We also compared the PLS regression method with a
simpler method based only on the correlations for all
miRNA-mRNA pairs. A correlation threshold of -0.750
corresponded to an estimated false detection rate of
2 . 5 0 % .T h eP L Sb a s e dm e t h o dw a sm o r es e n s i t i v ei n
detecting targets when applied to the actual data set;
only 33 miRNA-mRNA connections were declared to be
significant based on the correlation analysis with a
threshold -0.750, whereas 155 connections were signifi-
cant for the FDR threshold of 0.3.
Discussion
Integrative computational modeling of miRNA targets
using PLS
Although there are many computational algorithms for
predicting miRNA targets, they vary widely with regards
to specific targets identified. The relative usefulness of
these algorithms is strengthened if there are some agree-
ments in their conclusions. However, that is usually not
the case among the existing algorithms. Additionally,
the existing algorithms depend on the sequence comple-
mentarity of the miRNA-mRNA pairs. So, more com-
plex algorithms using joint expressions of miRNA and
mRNA may be useful to predict miRNA targets. In this
study we developed an approach for predicting miRNA-
mRNA associations based upon a statistical analysis
using unpaired t-tests, PLS regression based association
scores and the known inverse relationship between cer-
tain mRNAs and miRNAs.
Figure 5 Estimated false detection rates for different thresholds. Various thresholds for the q-values are on the x-axis. The estimated false
detection rate corresponding to each threshold is given on the y-axis. For the selected threshold of 0.3, the estimated false detection rate is
2.50%.
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Page 11 of 15Our efforts focused on a set of 31 significantly down-
regulated miRNAs and a set of 71 significantly up-regu-
lated mRNAs identified by the t-test for colon cancer vs.
the control samples after multiple hypotheses correc-
tions. We selected these miRNAs and mRNAs based on
their inverse relationship for our integrative analysis.
Using miRNAs as independent variables and mRNAs as
dependent variables in our PLS regression method we
identified significant miRNA-mRNA associations and in
turn predicted mRNA targets for individual miRNAs
(Table 1). When comparing these to miRNA-targets
predicted by TargetScan 5.1 and miRanda, we found on
average about 16.5% and 11.0% of our predicted targets
matched those predicted by these two programs, respec-
tively. Furthermore, some of our predicted target genes
lie within the union or intersection of the other two tar-
get prediction programs. It seems likely that the miRNA
target genes that lie within such intersections could be
more accurate, although this claim remains to be evalu-
ated further, experimentally. Interestingly, many of the
targets predicted by our methods are not predicted by
the other prediction algorithms and thus our approach
provides possible novel targets that need further investi-
gation for relevance to colorectal cancer {Step 7}. We
estimated the false detection rate of the proposed
method through a simulation study by sampling from
the real data under the null model. A limitation of the
present study is that we are unable to compute statisti-
cal performance measures such as the false discovery
rate since there does not exist any realistic simulator
currently for generating miRNA and mRNA datasets
simultaneously with controlled biological interactions
between them.
We have also compared our computational method of
target prediction with another computational method of
target prediction by association resulting from pairwise
simple correlations between all 31 the up-regulated
miRNAs and 71 down-regulated mRNAs. For the same
dataset using the same threshold we get many more tar-
g e t sa n ds ot h eP L Sb a s e dm e t h o dp r o v e dt ob em o r e
sensitive than just correlation based target prediction
described in Step 8 in the Results section.
Conclusion
In summary, we have developed a bioinformatics com-
putational approach for the analysis of miRNA and
mRNA expression profiles derived from the same set of
cancerous tissue samples to infer the molecular mechan-
ism for the colon cancer etiology. This analysis provides
an alternative computational approach to identify puta-
tive miRNA targets and reverse engineer the miRNA
networks with their mRNA targets. We have developed
a PLS modeling approach to take advantage of the
known inverse relationships between some miRNAs and
their target mRNAs. This approach would certainly have
to be modified for those situations where such a rela-
tionship does not exist. Our analysis resulted in 3 major
outcomes. 1) First, several of the predicted miRNA tar-
gets identified with our approach have also been pre-
dicted by other target prediction algorithms, which
provide some support for the development of our meth-
ods. 2) The PLS regression approach adopted here has
resulted in the recognition of novel miRNA-mRNA sets
(in turn miRNA targets). These putative data-sets could
provide better understanding of the underlined molecu-
l a rm e c h a n i s mo fc o l o nc a n c e ro ra n yo t h e rc o m p l e x
disease and identify novel therapeutic targets upon
experimental validations. 3) An in silico analysis of the
biological significance of the results obtained with our
PLS approach and pathway analysis indicates that pro-
cesses related to protein degradation and cell death per-
haps initiated by oxidative stress are likely involved in
colorectal cancer. This fact has been concluded by other
experimental studies [45]. Overall, it clearly shows that
these down-regulated miRNAs for colon cancer can
most likely be involved in many altered biological func-
tions along with their targets. The utility of our
approach and its possible applicability to other disease
states awaits further experimental validation.
Methods
miRNA and mRNA microarray data and gene expression
profile analysis
The miRNA and mRNA microarray data sets for both
human colon tumors and normal tissues used here
were obtained from the Broad Institute and down-
loaded from their web-accessible database: http://www.
broadinstitute.org/cgi-bin/cancer/datasets.cgi [20]. The
data sets originally consisted of five normal human tis-
sues and 10 human colon tumors for both miRNA and
mRNA. However, only four of the normal tissue sam-
ples and seven of the colon tumor samples passed
quality control criteria [46]. The mRNA expression
values were obtained using Affymetrix GENECHIP
analysis software (after hybridization to Affymetrix oli-
gonucleotide microarrays Hu6800 and Hu35KsubA)
containing a total of 16,063 probes [46]. The miRNA
median fluorescence intensity values were measured by
using a new, bead-based flow cytometric miRNA
expression profiling method. All data were filtered by
minimum value 32 (values less than 32 were consid-
ered as a background value according to the reference)
and log2 transformed [20].
The miRNA and mRNA expression data sets for colon
cancer patients were loaded into GeneSpring GX 10.0
(Agilent Technologies). An unpaired t-test was used to
compare miRNA and mRNA expressions for normal
and tumor tissue samples. The p-values obtained were
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Page 12 of 15then adjusted with the aid of the Benjamini-Hochberg
false discovery rate (FDR) [28] correction method. The
differentially expressed miRNAs or mRNAs with q-
values less than or equal to 10% and the absolute fold
changes greater than or equal to 1.2 were determined to
be significant.
miRNA target prediction using partial least square (PLS)
method and bootstrapping
An algorithmic version of the whole procedure is pro-
vided in Figure 1. A detailed description of the PLS
regression method used in this paper was previously
reported in [23] and [27]. Briefly, consider a data set
with n observations of p miRNAs (predictor variables)
and m mRNAs (response variables). Let Y =( Y1i,Y2i,. . . ,
Yni)’ be the column vector of observed values for the ith
mRNA;i = 1,2, ... ,m,a n dl e tXj =( X1j, X2j, ..., Xnj)’ be
the column vector of observed values for the jth miRNA
for j = 1,2, ...,p. For each mRNA Yi, PLS fits a regression
model of the form
ei
where ei is an n-dimensional vector of residuals and
t
(k)
i is the k-th latent variable amongst the set of all
orthogonal latent variables (l<<<p), all of which are lin-
ear combinations of the covariates. All of the original
variables are standardized before doing PLS.
Using ordinary least squares leads to
ˆ γik =
t
(k)t
i yi
t
(k)t
i t
(k)
i
,1≤ k ≤ n
and then the coefficients associated with the original
covariates can be obtained from the coefficients of the
latent variables.
Specifically, after q latent factors are found by select-
ing the number of component as 3, we calculated the
scaled score coefficient ˆ γik. Then the score coefficients
ˆ βij and intercept ˆ αi can be obtained by transforming ˆ γik
back to the original scale as follows ˆ βij =
q 
k=1
ˆ γik
ˆ σ(x)
ˆ σ(yi)
,
and
ˆ αi = ¯ yi − ˆ β 
ij¯ x. These coefficients are called the PLS
scores, and these scores are defined as the associations
between each response variable (mRNA) and the
miRNA covariate ˆ βij for a specific i and j.
Statistical test of the significance of the association
between miRNA and mRNA (bij)
In order to test the significance of the association
between miRNA and mRNA, we tested the null
hypothesis is H0: bij = 0, (which implies there is no sig-
nificant association between a specified miRNA and
mRNA) versus the alternative Ha: bij< 0( which implies
there is an inverse association between them). As we do
not know the asymptotic distribution of such associa-
tions we used a bootstrap re-sampling scheme to con-
struct the sampling distribution of the score bij for
testing the hypothesis.
We ran PLS after removing the jth miRNA gene, to
generate new bij and we compute the residual of the
model which is the estimate of the error ei.
After the residuals are computed, bootstrapping resi-
duals e∗
i1,e∗
i2,...,e∗
in are generated by simple random
sampling with replacement of the components ei1,ei2,...,
ein of the residual vector ei. Then the bootstrapped Y∗
i
data can be found by the original regression equation:
Y∗
i = αiJ +
p 
g=1 &g =j
βigXg + e∗
i .
where the parameters hold their usual meanings. We
then run PLS with the new Y∗
i a n do r i g i n a lf u l ls e to f
miRNAs, and store the bootstrapped PLS based score
β∗
ij. We did this bootstrapping step 1000 times for each
gene and calculate the proportion of times when the
negative bootstrapped association scores were smaller
than negative observed association score β∗
ij <β ij. These
proportions are the estimated p-values of the tests. The
Benjamini & Hochberg FDR [28] then is used to calcu-
late q-values. A threshold FDR was arbitrarily chosen as
0.3 since the number of variables in this test was small
after having identified the inverse relationship between
miRNA and mRNA. The associations for which the q-
values were less than equal to the FDR cutoff were
deemed to be significant.
Simulation Experiment
A simulation method similar in concept to the one pro-
posed in [22] was used to estimate the false detection
rate of possible targets using PLS regression for a speci-
fic threshold of FDR. The definition of the false detec-
tion rate was provided before in Step 8 of the Results
section, as described on page 4 of [22]. Note that the
concept of false detection rate refers to the simulation-
based estimate of the percentage of detected significant
miRNA-mRNA pairs derived by chance, and when using
this concept, we refer to it in full as false detection rate
so as not to confuse it with the abbreviation FDR which
we have already reserved for the more commonly-used
false discovery rate [28]. While we still use the FDR to
control false positives for our PLS method, we use the
false detection rate for this simulation to determine
equivalent thresholds for our method and for a simple
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based on FDR.
To generate a simulated data set with n “unassociated”
observations of p miRNAs and m mRNAs, we randomly
permuted the order of the n observations for both the
miRNA genes and the mRNA genes so that none of the
miRNA arrays corresponded to its true mRNA array.
Specifically, we randomly permuted the labels of both
arrays and rejected any generated data sets for which
the new labels matched. Therefore, since the miRNAs
do not correspond to the mRNAs in the simulated data
set, any low q-values only occur by chance. For the
simulated data set, we then compute the number of
false positives by counting the number of q-values
which fell below the threshold. The process was
repeated for 1000 simulated data sets and the estimated
false detection rate was computed by dividing the total
number of false positives for the 1000 data sets by the
overall total number of miRNA-mRNA pairs for the
1000 data sets.
We also compared the PLS regression with a simpler
method based only on the correlations for all miRNA-
mRNA pairs. In the correlation method, we declare that a
miRNA-mRNA pair is significant if the corresponding
pairwise correlation fell below a certain threshold. To
compare the sensitivity of the methods, we used the same
simulation method described above, and we chose the
threshold for which the estimated false detection rate was
the same as that found for the PLS regression method.
Biological function and pathway analysis
To obtain gene ontology (GO) terms for each miRNA,
we used Pathway Studio software (Ariadne Genomics
I n c . ,R o c k v i l l e ,M D ,U S A ) .T h i ss o f t w a r ee n a b l e da n
enrichment analysis of expressed genes for GO terms
using the differentially expressed miRNA target genes
with respect to the category of biological process. The
GO terms were selected by significant p-value and can-
cer-associated biological functions.
Using Ingenuity Pathway Analysis System and pathway
designer (IPA 8.5, Ingenuity Systems, Edwood, CA,
USA), we performed more detailed functional analysis
to identify miRNA-mediated, cancer-related and statisti-
cally significant networks, biological functions and cano-
nical signaling pathways for both differentially expressed
miRNAs and mRNAs.
Additional material
Additional file 1: Differentially expressed miRNAs in human colon
tissues. Supplemental Table 2 (S2): This file is a tab-delimited text file
and contains 2 up-regulated and 31 down-regulated miRNAs with FDR
corrected p-value less than 0.1 and absolute fold changes greater than
1.2. It also provides detailed information about each miRNA such as its
name, expression values and description.
Additional file 2: Differentially expressed mRNAs in human colon
tissues. Supplemental Table 1 (S1): This file is a tab-delimited text file
and contains 73 up-regulated and 63 down-regulated mRNAs with FDR
corrected p-value less than 0.1 and absolute fold changes greater than
1.2 It also provides detailed information about each mRNA such as its
name, expression values and description.
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